Evidence map›Paper›PMID 25649262›Full record

ArticleClinical and experimental vaccine research2015

Preliminary study on the immunogenicity of a newly developed GCC Tdap vaccine and its protection efficacy against Bordetella pertussis in a murine intranasal challenge model.

Seung Beom Han, Kyu Ri Kang, Dong Ho Huh, Hee Chul Lee, Soo Young Lee, Jong-Hyun Kim, Jae Kyun Hur, Jin Han Kang

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and experimental vaccine research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Seung Beom HanDepartment of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul, Korea. ; The Vaccine Bio Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Korea.ORCID 0000-0002-1299-2137
Kyu Ri KangThe Vaccine Bio Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Korea.ORCID 0000-0001-9135-1890
Dong Ho HuhThe Vaccine Bio Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Korea.ORCID 0000-0001-5395-7197
Hee Chul LeeThe Vaccine Bio Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Korea.ORCID 0000-0002-5715-7143
Soo Young LeeDepartment of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul, Korea. ; The Vaccine Bio Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Korea.ORCID 0000-0002-5354-3135
Jong-Hyun KimDepartment of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul, Korea. ; The Vaccine Bio Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Korea.ORCID 0000-0001-8641-7904
Jae Kyun HurDepartment of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul, Korea. ; The Vaccine Bio Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Korea.ORCID 0000-0002-3978-5787
Jin Han KangDepartment of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul, Korea. ; The Vaccine Bio Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Korea.ORCID 0000-0003-1610-6742
Catholic University of Korea · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeActive reduced dose tetanus-diphtheria-acellular pertussis (Tdap) vaccination for adolescents and adults is necessary because waning immunity after primary diphtheria-tetanus-pertussis vaccination is related to the recent emergence of pertussis. This study was conducted to compare the immunogenicity and protection efficacy against Bordetella pertussis between a new GCC Tdap vaccine and a commercially available Tdap vaccine in a murine model. MATERIALS AND

methodsBALB/c mice were immunized with two doses of diphtheria-tetanus-acellular pertussis (DTaP) vaccine for priming and a subsequent Tdap booster vaccination. According to the type of booster vaccine, mice were divided into four groups: commercially available Tdap vaccine in group 1 and GCC Tdap vaccines of different combinations of pertussis antigens in groups 2 to 4. Humoral and cell-mediated immune responses and protection efficacy using a murine intranasal challenge model after booster vaccination were compared among the four groups.

resultsEvery group showed significant increases in antibody titers against pertussis antigens such as pertussis toxin, filamentous hemagglutinin, and pertactin after booster vaccination. Spleen cells showed both Th1 and Th2 cell-mediated immune responses stimulated by pertussis antigens in all groups without any significant difference. In the intranasal B. pertussis infection model, bacteria were eradicated in all groups five days after challenge infection.

conclusionThis preliminary study did not show significantly different immunogenicity or protection efficacy of the new GCC Tdap vaccines compared to the commercially available Tdap vaccine, although a more extensive study is necessary to assess the differing efficacies of the new GCC Tdap vaccines.

Indexed as

Diphtheria-tetanus-acellular pertussis vaccineEfficacyImmunogenicityMiceRepublic of Korea

Identifiers

PMID25649262
PMCPMC4313112
OpenAlexW2068644387

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.